| |
FMD <4.2 % (n = 40 )
|
FMD ≥ 4.2 % (n = 40)
|
p
|
|---|
|
Age (years)
|
69.5 ± 7.1
|
69.4 ± 7.3
|
0.96
|
|
Female gender, n (%)
|
34 (85.0)
|
30 (75.0)
|
0.26
|
|
Body mass index
|
25.1 ± 3.4
|
23.6 ± 3.3
|
0.06
|
|
Diabetes mellitus, n (%)
|
23 (57.5)
|
22 (55.0)
|
0.82
|
|
Hypertension, n (%)
|
27 (65.7)
|
27 (67.5)
|
1.00
|
|
Dyslipidemia, n (%)
|
22 (55.0)
|
31 (77.5)
|
0.03
|
|
Current smoking, n (%)
|
10 (25.0)
|
11 (27.5)
|
0.80
|
|
Chronic renal insufficiency, n (%)
|
16 (40.0)
|
19 (47.5)
|
0.50
|
|
Previous PCI, n (%)
|
5 (12.5)
|
10 (25.0)
|
0.15
|
|
Previous myocardial infarction, n (%)
|
2 (5.0)
|
2 (5.0)
|
1.00
|
|
HDL cholesterol (mg/dl)
|
43.8 ± 11.2
|
49.3 ± 12.3
|
0.04
|
|
LDL cholesterol (mg/dl)
|
87.8 ± 28.1
|
88.1 ± 24.6
|
0.96
|
|
Triglycerides (mg/dl)
|
142.9 ± 73.6
|
113.7 ± 61.6
|
0.06
|
|
MDA-LDL cholesterol
|
97.9 ± 36.8 (n = 33)
|
82.2 ± 32.0 (n = 27)
|
0.62
|
|
Adiponectin
|
11.3 ± 5.2
|
12.0 ± 5.3
|
0.90
|
|
Medications
| | | |
|
Aspirin, n (%)
|
40 (100)
|
38 (95.0)
|
0.15
|
|
Clopidogrel, n (%)
|
35 (87.5)
|
33 (82.5)
|
0.53
|
|
ACE inhibitor/ARB, n (%)
|
35 (87.5)
|
30 (75.0)
|
0.15
|
|
ARB, n (%)
|
31 (77.5)
|
25 (62.5)
|
0.22
|
|
ACE inhibitors, n (%)
|
4 (10.0)
|
5 (12.5)
|
0.99
|
|
Perindopril
|
2 (5.0)
|
1 (2.5)
|
0.99
|
|
Imidapril
|
2 (5.0)
|
4 (10.0)
|
0.67
|
|
Statins, n (%)
|
36 (90.0)
|
36 (90.0)
|
1.00
|
|
Atorvastatin
|
4 (10.0)
|
7 (17.5)
|
0.52
|
|
Rosuvastatin
|
18 (45.0)
|
16 (40.0)
|
0.82
|
|
Pitavastaitn
|
14 (35.0)
|
13 (32.5)
|
0.99
|
|
β-blockers, n (%)
|
21 (52.5)
|
25(62.5)
|
0.37
|
- Data are expressed as mean ± SD or number (percentage)
- FMD Flow-mediated dilation, PCI Percutaneous coronary intervention, HDL High-density lipoprotein, LDL low-density lipoprotein, MDA-LDL Malondialdehyde-modified low-density lipoprotein, ACE Angiotensin-converting enzyme, ARB Angiotensin II receptor blocker
